白细胞介素-1B (IL-1B) 是一种有效的促炎细胞因子，在乳腺癌细胞与骨微环境之间的复杂相互作用中发挥着多种关键作用。 IL-1B参与原发性肿瘤的生长、肿瘤微环境内炎症的调节、促进上皮间质转化（EMT）、迁移和侵袭。此外，当乳腺癌细胞到达骨微环境时，IL-1B 会上调，从而促进为转移性乳腺癌细胞创造有利的生态位，并刺激骨转移恶性循环的启动。临床前研究表明，在各种小鼠模型中，抑制 IL-1 信号传导可减少雌激素受体阳性/三阴性乳腺癌的骨转移。然而，对原发性肿瘤和软组织转移的影响仍然存在争议，一些研究显示这些部位的肿瘤生长增加，而其他研究则没有显示任何影响。值得注意的是，抗 IL-1 疗法与化疗和免疫疗法等标准治疗相结合已被证明可以减少原发肿瘤的生长、骨转移以及其他器官的转移生长。本综述重点关注 IL-1B 促进乳腺癌骨转移的机制。© 2024 作者。由爱思唯尔有限公司出版。

Interleukin-1B (IL-1B) is a potent pro-inflammatory cytokine that plays multiple, pivotal roles, in the complex interplay between breast cancer cells and the bone microenvironment. IL-1B is involved in the growth of the primary tumours, regulation of inflammation within the tumour microenvironment, promotion of epithelial to mesenchymal transition (EMT), migration and invasion. Moreover, when breast cancer cells arrive in the bone microenvironment there is an upregulation of IL-1B which promotes the creation of a conducive niche for metastatic breast cancer cells as well as stimulating initiation of the vicious cycle of bone metastasis. Pre-clinical studies have demonstrated that inhibition of IL-1 signalling reduces bone metastasis from oestrogen receptor positive/triple-negative breast cancers in various mouse models. However, effects on primary tumours and soft tissue metastasis remain controversial with some studies showing increased tumour growth in these sites, whilst others show no effects. Notably, combining anti-IL-1 therapy with standard-of-care treatments, such as chemotherapy and immunotherapy, has been demonstrated to reduce the growth of primary tumours, bone metastasis, as well as metastatic outgrowth in other organs. This review focuses on the mechanisms by which IL-1B promotes breast cancer bone metastasis.© 2024 The Authors. Published by Elsevier GmbH.